Reilly Financial Advisors LLC Buys 102,761 Shares of Merck & Co., Inc. (NYSE:MRK)

Reilly Financial Advisors LLC increased its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 1,451.2% during the third quarter, HoldingsChannel reports. The fund owned 109,842 shares of the company’s stock after acquiring an additional 102,761 shares during the quarter. Reilly Financial Advisors LLC’s holdings in Merck & Co., Inc. were worth $9,247,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the stock. Fox Run Management L.L.C. grew its holdings in shares of Merck & Co., Inc. by 4.4% in the 3rd quarter. Fox Run Management L.L.C. now owns 2,827 shares of the company’s stock worth $238,000 after purchasing an additional 118 shares during the last quarter. Allworth Financial LP grew its holdings in shares of Merck & Co., Inc. by 1.9% in the 3rd quarter. Allworth Financial LP now owns 6,278 shares of the company’s stock worth $528,000 after purchasing an additional 119 shares during the last quarter. Stillwater Investment Management LLC grew its holdings in shares of Merck & Co., Inc. by 2.6% in the 2nd quarter. Stillwater Investment Management LLC now owns 4,796 shares of the company’s stock worth $402,000 after purchasing an additional 120 shares during the last quarter. Southeast Asset Advisors Inc. grew its holdings in shares of Merck & Co., Inc. by 2.3% in the 2nd quarter. Southeast Asset Advisors Inc. now owns 5,349 shares of the company’s stock worth $449,000 after purchasing an additional 120 shares during the last quarter. Finally, Pinnacle Bank grew its holdings in shares of Merck & Co., Inc. by 6.1% in the 3rd quarter. Pinnacle Bank now owns 2,120 shares of the company’s stock worth $178,000 after purchasing an additional 122 shares during the last quarter. 74.99% of the stock is currently owned by institutional investors and hedge funds.

NYSE MRK traded up $0.36 on Tuesday, hitting $85.05. 3,156,405 shares of the company were exchanged, compared to its average volume of 7,860,399. The firm has a 50 day moving average of $84.47 and a two-hundred day moving average of $82.27. The company has a market cap of $215.94 billion, a P/E ratio of 19.60, a P/E/G ratio of 1.71 and a beta of 0.53. The company has a current ratio of 1.21, a quick ratio of 0.92 and a debt-to-equity ratio of 0.82. Merck & Co., Inc. has a 1-year low of $66.10 and a 1-year high of $87.35.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, July 30th. The company reported $1.30 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.16 by $0.14. The business had revenue of $11.76 billion for the quarter, compared to the consensus estimate of $10.94 billion. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 43.34%. The firm’s quarterly revenue was up 12.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.06 EPS. Research analysts anticipate that Merck & Co., Inc. will post 4.92 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Monday, October 7th. Investors of record on Monday, September 16th were given a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, September 13th. This represents a $2.20 annualized dividend and a yield of 2.59%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 50.69%.

In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 6,427 shares of the company’s stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $85.09, for a total transaction of $546,873.43. Following the transaction, the executive vice president now directly owns 103,223 shares in the company, valued at approximately $8,783,245.07. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.27% of the stock is owned by corporate insiders.

Several research firms have recently weighed in on MRK. Argus upped their target price on shares of Merck & Co., Inc. to $105.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Bank of America set a $97.00 target price on shares of Merck & Co., Inc. and gave the stock a “buy” rating in a report on Thursday, July 11th. JPMorgan Chase & Co. set a $96.00 target price on shares of Merck & Co., Inc. and gave the stock a “buy” rating in a report on Thursday, October 10th. Citigroup upped their target price on shares of Merck & Co., Inc. from $84.00 to $95.00 and gave the stock a “buy” rating in a report on Friday, June 21st. They noted that the move was a valuation call. Finally, Leerink Swann assumed coverage on shares of Merck & Co., Inc. in a report on Thursday, August 15th. They issued an “outperform” rating and a $103.00 target price on the stock. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and sixteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $94.44.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Read More: Buy Rating

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.